Clinical Trials in Philadelphia

Showing 14901-14920 of 20,904 trials

Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

NCT01301456

The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.

Diabetes MellitusDiabetes Mellitus, Type 2Glucose Metabolism Disorders+2 more

Pfizer84 participantsStarted Mar 2011

Chula Vista, California, United States • Miami, Florida, United States • Miramar, Florida, United States +4 more locations

COMPLETEDPhase 1/2< 1 mile

Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT00068250

RATIONALE: Drugs used in chemotherapy such as methotrexate and temozolomide use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining methotrexate, temozolomide, and rituximab with radiation therapy may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of temozolomide when given together with methotrexate and rituximab followed by radiation therapy and to see how well they work in treating patients with primary central nervous system lymphoma.

Brain and Central Nervous System TumorsLymphoma

Radiation Therapy Oncology Group60 participantsStarted Jul 2003

Jacksonville, Florida, United States • Jacksonville, Florida, United States • Jacksonville, Florida, United States +23 more locations

Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Find Trials by Condition in Philadelphia

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

Expanded Access Program of Ponatinib

Diagnosis and Treatment of ACS in the ED: The Impact of Rapid Bedside cTnI Testing on Outcomes

IV Iron for the Anemia of Traumatic Critical Illness

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

An Open-Label Safety Study of A-101 Solution

Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

Study of Ruxolitinib in Colorectal Cancer Patients

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)

A Phase II Trial of Regadenoson in Sickle Cell Anemia

Using the Canary Breathing System for Panic Disorder Patients

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD

Environmental Triggers Of Cardiometabolic Disease

Evaluation of Primary Plating in Sternotomy Patients for Osteosynthesis and Pain

A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants